Our results demonstrate that MSLN plays a critical role in BM of NSCLC by modulating the JNK/MET signaling network and thus, provides a potential novel therapeutic target for preventing BM in NSCLC patients. This evidence concerns the gene MAPK8 and non-small cell lung carcinoma.